News and media, page-374

The loyalty options was an ugly episode in BGT history in half a year after IPO. The options were intended for shareholders who held from listing to the ex date, however, It was an administrative nightmare as it turned out. So those who pumped and stagged and subsequently bought back at lower prices also managed to be rewarded.

If you read through the prospectus of our IPO, most of our patents will expires next year, yes, 2022. These relate to pesticidal compositions to control insects etc, with betatriketones and betadiketones including flavesone and tasmanone. This will be the make or break year. The results could be binary.

Have we done any further steps to protect our IP? What if the big boys could then take the IP and develop their own manufacturing process?